Skip to main content
Home
Knowledge is power

Search

x

Swiss Medical Heroin Policy

  1. Home ⟶
  2. ⟶
  3. Swiss Medical Heroin Policy

"The harm reduction policy of Switzerland and its emphasis on the medicalisation of the heroin problem seems to have contributed to the image of heroin as unattractive for young people."

Source

Nordt, C., & Stohler, R. (2006). Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet (London, England), 367(9525), 1830–1834. https://doi.org/10.1016/S0140…

Main navigation

  • Home
  • Breaking News & Opinion
  • Chapters
  • Regions
  • Topics +
  • About Us
  • Privacy
  • Search

Chapters

  • AIDS and HIV
  • Addiction and Dependence
  • Alcohol
  • Amphetamine-Type Stimulants
  • Arrests, Law Enforcement, and the Criminal Legal System
  • Young People & Substance Use
  • Buprenorphine
  • Cannabis (Marijuana)
  • Capital Punishment
  • Causes of Death
  • CBD (Cannabidiol)
  • Chronic Pain
  • Civil Rights
  • Cocaine & Crack
  • Corruption
  • Crime
  • Dark Net Drug Markets & Cryptomarkets
  • Death Penalty
  • Demand Reduction
  • Diversion of Prescription Drugs
  • Driving, Drinking, and Drug Use
  • Drug and Alcohol Testing Overview
  • Drug Use Testing Related To Employment
  • Drug Use Testing Related To Schools
  • Drug Checking
  • Drugs and the Correctional System
  • Drug Courts
  • Drug Policies & Policy Reform
  • Drug Use Estimates
  • Economics
  • Ecstasy (MDMA)
  • Entheogens and Psychedelics
  • Environment
  • Families
  • Fentanyl
  • Forfeiture
  • Gateway Hypothesis
  • Harm Reduction
  • Hemp
  • Hepatitis C
  • Heroin
  • Heroin Treatment
  • HIV and People Who Inject Drugs
  • HIV, Race, and Injection Drug Use
  • Ibogaine
  • Interdiction
  • International
  • Jails
  • Kratom
  • Mandatory Minimums
  • Marijuana (Cannabis)
  • Medical Marijuana
  • Medication for Opioid Use Disorder
  • Mental Health and Substance Use
  • Mental Health Medications
  • Methadone
  • Methamphetamine
  • Militarization
  • Mushrooms (Psilocybin)
  • Naloxone
  • New Psychoactive Substances
  • Netherlands vs US
  • Overdose
  • Overdose Crisis
  • Overdose Prevention
  • Pain Management
  • Pregnancy
  • Prevention
  • Prisons, Jails, Probation, and Parole
  • Race and Prisons
  • Recovery
  • Supervised Consumption
  • Supply Reduction
  • Syringe Exchange
  • Tobacco
  • Treatment
  • Vivitrol (Naltrexone)
  • Women
  • Young People and Substance Use

Topics

  • Demand Reduction
  • Harm Reduction
  • Special Populations
  • Special Topics
  • Substances
  • Supply Reduction

Regions Outside U.S.

  • Australia
  • Austria
  • Belgium
  • Canada
  • Central Asia and Eastern Europe
  • Colombia
  • Denmark
  • European Union
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Mexico
  • Netherlands
  • Norway
  • Portugal
  • Russia
  • Scotland
  • Spain
  • Sweden
  • Switzerland
  • Ukraine
  • United Kingdom
© 2023 Drug Policy Facts, All rights reserved.
⇡